Page 2 - Bharat Biotech

Nasal vaccines for Covid-19: How do they work and what are their benefits?

The Drugs Controller General of India (DCGI), on Tuesday, approved Bharat Biotech's anti-covid vaccine for emergency use. It is the first such vaccine in the country

DCGI nod sought for phase-3 study of intranasal Covid vax in 5-18 age group

Hyderabad-based firm Bharat Biotech has sought permission from the drug regulator to conduct phase-3 study of its intranasal COVID-19 vaccine in the 5 to 18 age group. On September 6, the Drugs Controller General of India (DCGI) had approved its intranasal Covid vaccine iNCOVACC for restricted emergency use in those aged above 18 years. "Now the Hyderabad based firm has submitted an application seeking permission to conduct phase-3, multicenter study to evaluate the safety, reactogenicity and immunogenicity of iNCOVACC (BBV154) in those aged 18 to 5 years," an official source told PTI. iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase 1, 2 and 3 clinical trials with successful results, a release from the vaccine-maker said. BBV154 has been specifically formulated to allow intranasal delivery. "Being an intranasal vaccine, BBV154 may produce local antibodies in the up

Bharat Biotech awaits booster dose nod for intranasal vaccine iNCOVACC

Bharat Biotech did not comment on its plans to make this vaccine available for young children

LIVE: Union Cabinet approves policy on long-term leasing of Railways' land

300 cargo terminals will be developed in 5 years, says Union Minister Anurag Thakur on Union Cabinet decisions

India's first nasal vaccine for Covid-19 gets DCGI nod for emergency use

Bharat Biotech's iNCOVACC cleared for 2-dose regimen

Intranasal Covid vaccine will be global game changer: Bharat Biotech MD

Phase III trials were conducted for safety, and immunogenicity in about 3,100 subjects, in 14 trial sites across India

Bharat Biotech's intranasal Covid vaccine gets DCGI's nod for emergency use

The Drugs Controller General of India (DCGI) on Tuesday approved Bharat Biotech's intranasal Covid vaccine for restricted emergency use in those aged above 18 years. "Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation," Union Health Minister Mansukh Mandaviya tweeted. He said this step will further strengthen "our collective fight" against the pandemic. India has harnessed its science, research and development (R&D), and human resources in the fight against COVID-19 under Prime Minister Narendra Modi's leadership, he said. "With the science-driven approach & Sabka Prayas, we will defeat COVID-19," Mandaviya also said. The Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse

Fight against Covid-19: Here is a list of vaccines approved in India

Besides Bharat Biotech's nasal vaccine, India has 13 vaccines to fight against Covid-19. Two have been approved for manufacturing, while 11 have been approved for emergency use

Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'

The Hyderabad-based company claimed that BBV154 is proven to be safe, well-tolerated and immunogenic in the subjects under controlled clinical trials

Top headlines: Ola Electric to produce EVs in 2024; SBI hikes MCLR

SBI's overnight, one-month, and three-month MCLR stands at 7.35 per cent; six-month is at 7.65 per cent; one-year at 7.70 per cent; two-year at 7.90 per cent; and three-year MCLR stands at 8 per cent

Covid intranasal vaccine Phase III trials over, proven safe: Bharat Biotech

BBV154 was developed in partnership with Washington Univ St Louis, which had designed and developed recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy

Serum Institute explores new-age vaccine delivery systems for growth

The Pune-based company that manufactured the Covid-19 vaccine administered to most Indians is exploring more sophisticated delivery systems

Bharat Biotech expects regulator's nod for intranasal Covid vaccine in Aug

The Drug Controller General of India gave its nod to conduct clinical trials for BBIL's intranasal vaccine as booster dose

Bharat Biotech, ExcellGene consortium to develop variant-proof Covid vax

The consortium is developing or designing a new vaccine concept that confers highly cross-reactive protection against numerous SARS-CoV-2 variants of concern

Covaxin third shot gives long-term immunity: Nature Scientific study

Study shows booster jab is effective against several Sars-CoV-2 strains such as Alpha, Beta, Delta, Delta Plus and Omicron, and also increases memory B-cell response

Top Headlines: PSBs shareholding cap, growth of top firms, and more

The central government is seeking to remove the 10 per cent shareholding cap for individuals in public sector banks (PSBs). Read more in our top headlines

Bharat Biotech's Zika vaccine to enter Phase 2 clinical trials soon

In 2016, Big Pharma companies like Pfizer, Johnson & Johnson, and Merck were evaluating developing a Zika vaccine

Bharat Biotech's Covaxin induces wider immune response, say experts

However, experts say that Covaxin induces a wider immune response and thus antibody production against the spike protein may be less intense

Twitter accounts hyped US firm seeking trials for India-made Covid vaccine

Ocugen sought FDA approval for Covaxin in October, then a seeming coordinated social media effort lifted its stock.

Bharat Biotech's Covaxin is safe for children between 2 and 18 yrs: Lancet

Data from over 50 million doses reveals minimal side effects